DRRX
Durect Corp
Halal Rating :
Last Price
$0.84
Last updated:
Market Cap
-
7D Change
1.82%
1 Year Change
10.53%
Company Overview
Industries
Exchange
Next Earnings Date
Durect Corporation is a biopharmaceutical company focused on developing therapeutics based on its epigenetic regulator program. The company's lead drug candidate is Larsucosterol (DUR-928), an endogenous small molecule that is in clinical development for the treatment of alcohol-associated hepatitis (AH) and non-alcoholic steatohepatitis (NASH).
The company also has a legacy business segment that develops and manufactures pharmaceutical products based on its proprietary drug delivery technologies.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.93m | $5.89m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $2.17m | $5.58m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1.83m | $7.54m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Durect Corp's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.